Form 13-F position report

PLUS THERAPEUTICS INC

Reported by GEODE CAPITAL MANAGEMENT LLC

PSTV CUSIP 72941H509 Manager CIK 0001214717

Reported 0 shares, down 2,016,314 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2026
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 21 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 271000
2022-03-31 258000
2022-06-30 139000
2022-09-30 115000
2022-12-31 81000
2023-03-31 73993
2023-06-30 34354
2023-06-30 0
2023-09-30 35567
2023-12-31 47511
2024-03-31 52819
2024-06-30 68572
2024-09-30 79239
2024-12-31 66872
2025-03-31 54205
2025-06-30 17798
2025-09-30 556018
2025-12-31 719028
2026-03-31 327979
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for PLUS THERAPEUTICS INC held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -2,016,314 (-100.0%) 0 $0 2026-08-12
Q1 2026 Added 2,016,314 +613,520 (43.7%) < 0.01% $327,979 2026-05-15
Q4 2025 Added 1,402,794 +589,544 (72.5%) < 0.01% $719,028 2026-02-09
Q3 2025 Added 813,250 +762,074 (1489.1%) < 0.01% $556,018 2025-11-12
Q2 2025 Reduced 51,176 -5,877 (-10.3%) < 0.01% $17,798 2025-08-08
Q1 2025 Reduced 57,053 -1,097 (-1.9%) < 0.01% $54,205 2025-05-13
Q4 2024 Added 58,150 +3,876 (7.1%) < 0.01% $66,872 2025-02-12
Q3 2024 Added 54,274 +7,626 (16.3%) < 0.01% $79,239 2024-11-12
Q2 2024 Added 46,648 +17,385 (59.4%) < 0.01% $68,572 2024-08-09
Q1 2024 Added 29,263 +2,720 (10.2%) < 0.01% $52,819 2024-05-13
Q4 2023 Unchanged 26,543 0 (0.0%) < 0.01% $47,511 2024-02-13
Q3 2023 Added 26,543 +9,536 (56.1%) < 0.01% $35,567 2023-11-13
Q2 2023 Reduced 0 -255,148 (-100.0%) 0 $0 2023-08-11
Q2 2023 New 17,007 +17,007 (0.0%) < 0.01% $34,354 2023-08-11
Q1 2023 Reduced 255,148 -2,904 (-1.1%) < 0.01% $73,993 2023-05-15
Q4 2022 Reduced 258,052 -385 (-0.1%) < 0.01% $81,000 2023-02-13
Q3 2022 Unchanged 258,437 0 (0.0%) < 0.01% $115,000 2022-11-14
Q2 2022 Unchanged 258,437 0 (0.0%) < 0.01% $139,000 2022-08-12
Q1 2022 Unchanged 258,437 0 (0.0%) < 0.01% $258,000 2022-05-13
Q4 2021 Unchanged 258,437 0 (0.0%) < 0.01% $271,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

24 managers reported PLUS THERAPEUTICS INC for Q2 2026.

Managers reporting PLUS THERAPEUTICS INC in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MILLENNIUM MANAGEMENT LLC Reduced 0 -271,599 0 $0 2 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 0 -2,427,098 0 $0 2 qtrs
XTX Topco Ltd Reduced 0 -116,023 0 $0 3 qtrs
DAGCO Inc Reduced 0 -25,882 0 $0 4 qtrs
UBS Group AG Reduced 0 -87,850 0 $0 6 qtrs
Citigroup Inc Reduced 0 -93,002 0 $0 3 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Reduced 0 -2,016,314 0 $0 13 qtrs
Miller Financial Services LLC Reduced 0 -50,000 0 $0 2 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 0 -133 0 $0 13 qtrs
DANSKE BANK A S Reduced 0 -1 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 12, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.